Soft Tissue Sarcomas

Soft tissue sarcomas (STS) are a rare and diverse group of malignant tumors that arise from the mesenchymal tissues, including fat, muscle, blood vessels, and connective tissues. At Alfa Cytology, we are committed to helping our clients unravel the complexity of these diseases by providing integrated preclinical research solutions.

Introduction to Soft Tissue Sarcomas

Soft tissue sarcomas account for less than 1% of all cancer diagnoses, yet they pose significant challenges in terms of early detection, effective treatment, and patient outcomes. Soft tissue sarcomas are considered an orphan disease due to their rarity, which often leads to a delay in diagnosis and subsequent management.

Pathogenesis of Soft Tissue Sarcomas

One of the key drivers of soft tissue sarcoma development is the dysregulation of fundamental cellular processes, such as cell growth, differentiation, and apoptosis. Alterations in signaling pathways, including the PI3K/Akt/mTOR, RAS/MAPK, and Rb/p53 pathways, have been implicated in the pathogenesis of various STS subtypes. Additionally, chromosomal instability, leading to structural and numerical aberrations, is a hallmark of many soft tissue sarcomas.

Fig.1 Oncogenic activity of TBX3 and nucleolin in sarcomas. (Tam, Y. B., et al., 2021)

Current Therapeutic Strategies for Soft Tissue Sarcomas

The rarity and heterogeneity of STS complicates the approach to treating this complex disease. The various subtypes of STS pose significant challenges due to their histological specific signalling pathways, prognostic factors, and inherent variability in response to conventional therapy. Recently, significant progress has been made in thetherapy of STS using targeted therapies, such as γ-Secretase inhibitors, Murine Double Minute Clone 2 (MDM2) inhibitors, BRD9 inhibitors, etc.

Our Services

At Alfa Cytology, our team of molecular biologists and geneticists employs state-of-the-art techniques, such as next-generation sequencing and functional genomics, to elucidate the complex pathways involved in STS development. By utilizing cutting-edge technologies and an in-depth understanding of the underlying biology, we are committed to developing diagnostics and novel therapies that are effective against soft tissue sarcoma.

At Alfa Cytology, we are committed to providing comprehensive and cutting-edge solutions for the management of soft tissue sarcomas. For more information about our soft tissue sarcoma research and development initiatives, or to inquire about our comprehensive services, please don't hesitate to contact us.

For research use only.